Regulamentos administrativos e a concessão de patentes para medicamentos de segundo uso médico
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
DOI
Abstract
The following empirical-qualitative research in law had the objective of understanding
the standards used by the Instituto Nacional da Propriedade Industrial (INPI) in evaluating
patent claims for new uses of existing medicines, the phenomenon of the follow-on drugs. We
sought to answer the following question: from the document analysis of the patent claims for
Remdesivir, what are the normative and regulatory bases used by the INPI in the deposits
involving patents for second medical use, based on the analysis of the tension between access
to medicines and industrial property in the brazilian context? The documentary analysis was
based on Cellard's (2005) techniques, with public data collected from the INPI patent search
platform. In the case of empirical research in law, the methodological rules of Epstein and King
(2013) were taken into account. The collection was interpreted using the theoretical substrate
of Bankowski (2006), regarding the interaction between the legal and the moral in the context
of the patent legal system. It was concluded that the INPI allows the possibility of patent claims
for follow-on drugs using the Swiss-type claims, and resolutions no. 262/2011, n. 169/2016 and
n. 208/2017 are used as guidelines for analyzing these types of patent claims in Brazil.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Embargado

